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ABSTRACT
We analyzed the incidence, etiology, risk factors, and clinical management of hemorrhagic cystitis (HC) in 102
children who underwent allogeneic stem cell transplantation: 28 from matched siblings, 57 from unrelated
donors, and 17 from mismatched relatives. Conditioning regimens consisted of high-dose chemotherapy (n 
83) or total body irradiation (n  19). In all children, urine and plasma were prospectively screened for human
polyomavirus (HPV; BK virus [BKV] and JC virus [JCV]) or adenovirus (AdV) DNA with a polymerase chain
reaction–based assay. Viral DNA was detected in the urine of 56 children (54.9%): BKV in 48 (47%), JCV in
4 (3.9%), and AdV in 4 (3.9%). HC occurred in 26 children (25.5%), and viruria was detected in all of them:
BKV in 21 (80.8%), AdV in 4 (14.4%), and JCV in 1 (3.8%). All patients with AdV viruria developed HC. The
cumulative incidence of HC in patients with HPV viruria was 0.43. The only significant risk factor for HC in
patients with HPV-positive urine was conditioning with high-dose chemotherapy. Twenty-two children were
treated with cidofovir, with no significant toxicity. In all treated patients but 1, the clinical symptoms were
moderate, and no HC-related death was observed. We conclude that virus-induced HC is a frequent compli-
cation after allogeneic hematopoietic cell transplantation. Treatment with cidofovir is feasible, and further
studies are warranted to evaluate its activity in HC mediated by BKV or JCV.
© 2005 American Society for Blood and Marrow Transplantation
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1NTRODUCTION
Hemorrhagic cystitis (HC), referring to the syn-
romes of urinary tract irritability and hematuria, is
ecognized as a signiﬁcant cause of morbidity and,
ccasionally, mortality in stem cell or renal transplant
ecipients [1-5]. Its incidence ranges from 6% to 30%
n patients undergoing allogeneic hematopoietic cell
ransplantation (alloHCT) [3,4,6].
Clinical manifestation varies from microscopic to
ross hematuria with clot formation that can lead to i
B&MTrinary tract obstruction and sometimes renal failure
7,8]. The early-onset HC that occurs during or
hortly (up to 48 hours) after high-dose chemotherapy
s mainly related to oxazaphosphorine drugs (cyclo-
hosphamide [Cy] and ifosfamide) or busulfan (Bu)
9,10]. In cases of late-onset HC (later than 48 hours
fter completion of conditioning), viral infections with
uman polyomaviruses (HPV) such as BK virus (BKV)
nd JC virus (JCV) or adenovirus (AdV), mainly type
1, have been documented [11-15]. Some data also
ndicate cytomegalovirus, human herpesvirus 6, and,
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7ecently, simian virus 40 as putative agents of
C [16-18]. The management of HC is generally
ymptomatic. Hyperhydration, forced diuresis, and
onstant bladder irrigation are commonly accepted
reatment methods [6,14]. Local administration of
nti-inﬂammatory or hemostatic agents such as alum,
ormalin, or prostaglandin E1 has been described, but
heir efﬁcacy remains controversial [19-21]. Conju-
ated estrogens may also improve the outcome [22].
n the case of severe urinary tract obstruction, a sur-
ical approach including cystectomy must be consid-
red to preserve renal function [23].
Over the last decade, encouraging results with
ntiviral agents such as vidarabine, ribavirin, and, re-
ently, cidofovir have been published; however, they
ere used in a small number of patients and are still
ot deﬁned as a standard therapeutic option [24-27].
he aim of our study was to evaluate the incidence,
tiology, risk factors, clinical outcome, and manage-
ent of HC in children and adolescents after allo-
CT.
ETHODS
atient Characteristics
Between May 2001 and September 2004, 102 pa-
ients who underwent alloHCT in the Department of
ediatric Hematology, Oncology and Bone Marrow
ransplantation, Wroclaw Medical University, were
tudied prospectively. Patient characteristics are pre-
ented in Table 1.
There were 38 girls and 64 boys aged from 6
onths to 20 years. Twenty-eight received transplants
able 1. Patient Characteristics (n  102)
Variable Data
ge
Median, y (range) 11 (0.5-20.3)
<5 y (n) 29
>5 and <10 y (n) 20
>10 y (n) 53
ex (M/F) 64/38
iagnosis
Malignancies 88
Nonmalignant diseases 14
ype of donor
MSD 28
UD 57
PMFD 17
onditioning
TBI based 19
Chemotherapy only 83
VHD prophylaxis
CsA  MTX 23
In vivo T-cell depletion  CsA/MTX 63
Ex vivo  in vivo T-cell depletion 16
SD indicates matched sibling donor; UD, unrelated donor;
PMFD, partially matched family donor; TBI, total body irradi-Aation; CsA, cyclosporin A; MTX, methotrexate.
98rom matched sibling donors (MSD); 57, from unre-
ated donors (UD); and 17, from partially matched
amily donors (PMFDs). The conditioning regimen
ncluded total body irradiation (TBI) plus VP-16 (n 
9) or chemotherapy only (n  83): (1) Bu plus Cy
ith or without other drugs (n 50), (2) Bu plus other
rugs (n  12), (3) Cy with or without other drugs
n  12), or (4) other combinations of drugs without
u or Cy (n  9). In patients who received transplants
rom alternative donors and in all patients with non-
alignant diseases, irrespective of the donor type, in
ivo T-cell depletion (antithymocyte globulin or
abCampath [Schering AG, Germany]) was included
n the preparative regimen. Patients who received
ransplants from PMFDs additionally received
KT3. Graft-versus-host disease (GVHD) preven-
ion consisted of cyclosporin A with or without meth-
trexate in patients with malignancies who received
ransplants from MSDs or of cyclosporin A plus meth-
trexate in all patients who received transplants from
Ds and patients with nonmalignant diseases who
eceived transplants from MSDs. All children who
eceived transplants from PMFDs were grafted with
x vivo T cell–depleted hematopoietic cells. The pa-
ients who received transplants from PMFDs with ex
ivo and in vivo T-cell depletion were signiﬁcantly
ounger (P  .001) than those who received trans-
lants from MSDs or UDs.
iagnosis of HC
HC was deﬁned as the presence of sustained he-
aturia and symptoms of lower urinary tract irritabil-
ty, such as dysuria with frequency and urgency, in the
bsence of other conditions, such as vaginal bleeding,
eneralized bleeding diathesis, and bacterial or fungal
rinary tract infection. Standard urine analysis was
erformed at least twice a week throughout the post-
ransplantation hospitalization and afterward at con-
rol visits.
In all patients with hematuria, genitourinary ultra-
onography was performed. Ultrasonographic ﬁnd-
ngs such as the thickening of the bladder mucosa and
he presence of clots in the bladder were used in the
ifferential diagnosis of hematuria [35].
The severity of HC was assessed according to the
riteria proposed by Droller [28]: grade 1, microscopic
ematuria; grade 2, macroscopic hematuria; grade 3,
acroscopic hematuria with small clots; and grade 4,
ross hematuria with clots causing urinary tract ob-
truction requiring instrumentation for clot evacua-
ion.
irus Detection
Blood and urine samples were prospectively
creened for the presence of HPV (BKV and JCV) and
dV by using a qualitative polymerase chain reaction
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BPCR)–based method. The samples were collected
very 7 to 14 days throughout hospitalization and later
t the outpatient clinic. Viral DNA was detected in the
cellular fraction of urine after centrifugation. This
ssay was optimized for the detection of infection in
he active (replicative) but not in the latent stage.
The primer pair 5=-AGT CTT TAG GGT CTT
TA CC-3= and 5=-GGT GCC AAC CTA TGG
AC AG-3= was used to obtain a 176–base pair am-
licon from the BKV genome and, in the same reac-
ion, the 173–base pair sequence of JCV DNA. Di-
estion of the PCR products with BamHI before
lectrophoresis was used to discriminate between
KV and JCV sequences. The JCV sequence targeted
or ampliﬁcation contained a BamHI site and was
leaved into fragments of 120 and 53 base pairs. The
mpliﬁcation product from the BKV genome was not
leaved by BamHI. The PCR products were visualized
fter electrophoresis in 2% agarose gel stained with
thidium bromide. For identiﬁcation of AdVs, the
rimer pair 5=-GCC GAG AAG GGC GTG CGC
GG TA-3= and 5=-ATG ACT TTT GAG GTG
AT CCC ATG GA-3=, common for all serotypes,
as used.
C Prophylaxis
Hyperhydration with intravenous administration
f isotonic saline and glucose solution (3 L/m2/d) was
tarted at least 12 hours before and continued for 24
ours after the preparative high-dose chemotherapy
as completed. In addition, patients treated with Cy
able 2. Results of Viral Screening
Variable BKV or
ge, n (%)
<5 y (n  29) 5 (17.
>5 and <10 y (n  20) 10 (50%
>10 y (n  53) 37 (69.
ex
M (n  64) 32 (50%
F (n  38) 20 (52.
iagnosis
Malignancies (n  88) 47 (53.
Nonmalignant diseases (n  14) 5 (35.
ype of donor
MSD (n  28) 14 (50%
UD (n  57) 36 (63.
PMFD (n  17) 2 (11.
onditioning
TBI based (n  19) 12 (63.
Chemotherapy only (n  83) 40 (48.
VHD prophylaxis
CsA  MTX (n  23) 12 (52.
In vivo T-cell depletion (n  63) 38 (60%
Ex vivo  in vivo T-cell depletion (n  16) 2 (12.
otal (n  102) 52 (51%
SD indicates matched sibling donor; UD, unrelated donor; PM
cyclosporin A; MTX, methotrexate; AdV, adenovirus; BKV, human po
B&MTeceived 2-mercaptoethane sulfonate (mesna) uropro-
ection at a total dose twice higher than Cy (25% in a
olus before Cy administration; the remaining 75%
as added to the saline/glucose infusion).
anagement of HC
Hyperhydration with continuous infusion of nor-
al saline and glucose (3 L/m2/d), together with con-
ugated estrogens at a dose of 1.5 to 5 mg/d, was given
o all patients with HC. In patients with grade 3 HC,
bladder catheter was installed if urine output was
isturbed. Children with HC grade 4 underwent cys-
oscopic evacuation of clots and suprapubic catheter
nstallation for continuous bladder irrigation with
ormal saline. From May 2002, 22 patients with viru-
ia and HC grade 2 were treated with cidofovir.
wenty received cidofovir 5 mg/kg: ﬁrst twice weekly
nd then fortnightly until resolution of clinical symp-
oms. In 1 patient, cidofovir was administered weekly.
ne child with renal function impairment due to
hrombotic thrombocytopenic purpura/hemolytic
remic syndrome received a reduced dose (1 mg/kg)
f cidofovir. Oral probenecid was given 3 hours before
idofovir and 1 and 8 hours afterward. Serum creati-
ine concentration was measured at least twice a week
uring cidofovir treatment.
VHD Grading
GVHD was assessed and graded according to
lingebiel and Schlegel [29].
rine Plasma
AdV BKV or JCV AdV
1 (3.4%) 1 (3.4%) 2 (6.8%)
1 (5%) 2 (10%) 0
2 (3.8%) 8 (15.1%) 6 (11.3%)
1 (1.6%) 6 (9.4%) 5 (7.8%)
3 (7.9%) 5 (13.2%) 3 (7.9%)
4 (4.5%) 11 (12.5%) 8 (9.1%)
0 0 0
1 (3.6%) 1 (3.6%) 1 (3.6%)
2 (3.5%) 9 (15.8%) 5 (8.8%)
1 (5.9%) 1 (5.9%) 2 (11.8%)
0 1 (5.3%) 1 (5.3%)
4 (4.8%) 10 (12%) 7 (8.4%)
1 (4.3%) 1 (4.3%) 1 (4.3%)
2 (3.2%) 9 (14.5%) 5 (8.1%)
1 (5.9%) 1 (5.9%) 2 (11.8%)
4 (3.9%) 11 (10.8%) 8 (7.8%)
artially matched family donor; TBI, total body irradiation; CsA,U
JCV
2%)
)
8%)
)
6%)
4%)
7%)
)
2%)
8%)
2%)
2%)
2%)
)
5%)
)
FD, p
lyoma BK virus; JCV, human polyoma JC virus.
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8tatistical Methods
The cumulative incidence of HC was estimated
ith intervals starting at alloHCT to the ﬁrst day of
ematuria. The cumulative incidence of HPV infec-
ion was estimated with intervals starting at alloHCT
o the day of the ﬁrst virus-positive urine sample.
ompeting event was deﬁned as death before day 100
fter transplantation without symptoms of HC or
ithout HPV viruria. The univariate and multivariate
nalysis of potential HC risk factors and risk factors
or HPV positivity—including age, sex, disease, con-
itioning, donor type, immunosuppression, and severe
cute GVHD—were performed with the Cox propor-
ional hazard model. Only risk factors signiﬁcant in
nivariate analysis (P  .05) were included in the
ultivariate model. The differences in age between
atients group were analyzed with the Mann-Whitney
test.
ESULTS
dentification of Viruses
The results of viral screening are presented in
able 2. Viral DNA was found in urine samples ob-
ained from 56 patients (54.9%). BKV was the most
requent and was present in the urine of 48 children
47%) and in the serum of 10 patients (9.8%). In all 10
atients, BKV viremia accompanied viruria. JCV was
etected in urine of only 4 patients (3.9%) and in 1 of
hese was also present in serum. In univariate analysis,
o ex vivo T-cell depletion and older age were asso-
iated with HPV viruria (P  .001). However, in
ultivariate analysis, only age remained signiﬁcant (P
.005; relative risk, 1.86). AdV was detected in the
rine of 4 patients (3.9%) and in the serum of 8
hildren (7.8%). In 3 children (2.9%), AdV was
resent in both urine and serum; in 1 (0.98), it was
resent exclusively in urine.
ncidence of HC
HC was diagnosed in 26 (25.5%) patients. No
atient had sustained microscopic hematuria only and
ymptoms of lower urinary tract irritation; therefore,
o HC grade 1 was observed. HC distribution across
atient groups is presented in Table 3. In all patients
ith HC, viral DNA was present in the urine. BKV
as the most frequently identiﬁed virus among chil-
ren with symptoms of cystitis. It was detected in 21
80.8%) patients. AdV was found in 4 (15.4%) chil-
ren, and JCV was found in only 1 child (3.8%).
HC was less frequent in the group of children
ounger than 5 years (6.9%) and, surprisingly, in pa-
ients who received transplants from PMFDs with ex
ivo and in vivo T cell–depleted grafts (6.26%). The (
00requency of HC in children with severe acute GVHD
grade III or IV) and mild or no acute GVHD (grade
to II) was similar (30.4% versus 24.1%, respectively;
ot signiﬁcant). HC occurred in only 1 (5.3%) child
ut of 19 conditioned with TBI.
linical Outcome and Treatment
HC in HPV-positive patients. The cumulative inci-
ence of HC in patients with BKV or JCV viruria
as estimated at 0.43 (95% conﬁdence interval, 0.31-
.58). HC developed in 9 patients who received trans-
lants from MSDs, in 13 who received transplants
rom UDs, and in none who received transplants from
MFDs. Seven children with HC had concomitant
ymptoms of severe acute GVHD. However, the only
igniﬁcant risk factor for HC in patients with HPV
iruria was the type of conditioning. HC was diag-
osed in only 1 patient (8.3%) with TBI conditioning
nd in 21 (52.5%) children conditioned with high-
ose chemotherapy. The cumulative incidence curves
f HC for HPV-positive patients with different con-
itioning regimens are presented in Figure 1.
HC occurred in 21 (43.7%) of 48 patients with
KV viruria, including 8 of 10 children with concom-
tant BKV viremia. The median HC onset time was 45
ays (range, 8-88 days) after stem cell transplantation
able 3. Incidence of HC
Variable
No. Patients
with HC (%)
otal 26 (25.5%)
ge (y)
<5 (n  29) 2 (6.9%)
>5 and <10 (n  20) 3 (15%)
>10 (n  53) 21 (39.6%)
ex
M (n  64) 17 (26.6%)
F (n  38) 9 (23.7%)
iagnosis
Malignancies (n  88) 24 (27.3%)
Nonmalignant diseases (n  14) 2 (14.3%)
ype of donor
MSD (n  28) 10 (35.7%)
UD (n  57) 15 (26.3%)
PMFD (n  17) 1 (5.9%)
onditioning
TBI based (n  19) 1 (5.3%)
Chemotherapy only (n  83) 25 (31%)
VHD prophylaxis
CsA  MTX (n  23) 8 (34.8%)
In vivo T-cell depletion  CsA/MTX (n  63) 17 (27%)
Ex vivo  in vivo T-cell depletion (n  16) 1 (6.26%)
cute GVHD grade
0–II (n  79) 19 (24.1%)
III–IV (n  23) 6 (30.4%)
SD indicates matched sibling donor; UD, unrelated donor;
PMFD, partially matched family donor; TBI, total body irradi-
ation; CsA, cyclosporin A; MTX, methotrexate; GVHD, graft-
versus-host disease.SCT). In 2 patients with HC stage 2, hematuria
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Besolved after 6 and 52 days of symptomatic treatment
nly. Nineteen children with HC greater than stage 2
eceived cidofovir. In 15 (78.9%) of these, HC re-
olved after a median of 22 days (range, 9-63 days) of
ematuria and short treatment with cidofovir (median,
doses). The resolution of HC was accompanied by
radication of BKV from the blood in all patients and
rom the urine in 6. Three children died of causes
ther than HC with persistent hematuria lasting from
2 to 41 days. Only in 1 patient did HC progress to
rade 4 during cidofovir treatment, but this ﬁnally
esolved after 80 days. One patient out of 4 with JCV
iruria presented with HC on day46. In this patient,
CV viremia was also documented. The child received
dose of cidofovir but died as a result of severe
eno-occlusive disease and sepsis with persistent he-
aturia lasting 10 days.
HC in AdV-positive patients. All 4 patients with
dV viruria were diagnosed with HC between day3
nd day 31. In 3 of them, AdV viremia was also
ocumented. Two patients who underwent transplan-
ation before May 2002 did not receive cidofovir and
ied with symptoms of stage IV HC, which lasted 43
nd 44 days. In one patient, HC rapidly progressed,
ith urinary tract obstruction and bladder tamponade
ollowed by renal failure, which was the main cause of
eath. The second untreated child died as a result of
nterstitial pneumonia in the course of disseminated
dV infection with persistent severe hematuria. Two
dV-positive patients who underwent transplantation
fter May 2002 were treated with cidofovir. One child,
igure 1. Cumulative incidence of HC in patients with HPV viruria
L, conﬁdence limits; CHT, chemotherapy.ith AdV present in both the urine and blood, was c
B&MTiven 10 doses of cidofovir. Hematuria resolved after
9 days and was followed by the eradication of AdV.
nother AdV-positive patient (who received a trans-
lant from an MSD), who received 4 doses of cidofo-
ir, died with symptoms of moderate HC that lasted
9 days and persistent AdV viruria caused by over-
helming lymphoma.
idofovir Tolerance
Two patients with HPV-induced HC who re-
eived 1 dose of cidofovir died 8 and 37 days later
ecause of multiorgan failure in the course of severe
eno-occlusive disease or sepsis. In these patients, ci-
ofovir toxicity was not possible to assess.
In 1 patient with BKV-induced HC, thrombotic
hrombocytopenic purpura/hemolytic uremic syn-
rome was concomitantly present. The patient’s base-
ine creatinine concentration was 251.94 mol/L;
herefore, 2 doses of cidofovir were reduced to 1
g/kg. No further increase in creatinine level (197.13
mol/L) after treatment was observed. In the remain-
ng 21 patients, the maximal creatinine concentration
uring and after cidofovir treatment ranged from
9.78 to 152.93 mol/L (median, 87.52 mol/L). One
f these patients experienced reversible acute renal
ailure that necessitated hemodialysis in the course of
evere veno-occlusive disease, before cidofovir treat-
ent. Also in this patient, no renal toxicity was ob-
erved after 3 doses of cidofovir (maximum creatinine
e of conditioning (n  52). Cum In indicates cumulative incidence;by typoncentration, 56.58 mol/L).
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8isk Factors for HC
HC occurred only in patients with PCR-positive
rine. Because few patients had AdV and because all
dV-positive patients developed HC, thus suggesting
strong relationship between AdV positivity and dis-
ase, such patients were excluded from further analy-
is. The Cox model was applied to a more homoge-
ous group of patients with BKV or JCV viruria to
dentify additional risk factors for HC. Only chemo-
herapy-based conditioning proved to be signiﬁcant in
nivariate analysis; therefore, no multivariate explora-
ion was applied. There was no difference in the rel-
tive risk of HC between children who received the
ombination of Bu and Cy in the conditioning regi-
en and children conditioned with other combina-
ions of cytostatics. The results of the statistical anal-
sis are presented in Table 4.
ISCUSSION
Over the past decade, increasing attention was
ocused on late-onset HC, which is a signiﬁcant cause
f morbidity and, occasionally, mortality in hemato-
ogic stem cell recipients [1,2,6,14,31-33]. This com-
lication, mainly related to BKV reactivation and
haracterized by prolonged hematuria and painful
ysuria, resolves spontaneously in most patients.
able 4. Statistical Analysis (Cox Model)
Variable P Value RR
95% CL
Lower Upper
ex
Female .140 .493 .193 1.261
Male — 1
ge .095 2.161 .876 5.332
ype of donor
PMFD .979 — — —
UD .190 .566 .242 1.325
MSD — 1 — —
onditioning
Chemotherapy with Bu
and Cy .03 9.37 1.23 71.04
Other chemotherapy .04 8.47 1.02 70.83
TBI — 1 — —
iagnosis
Malignancies .847 .867 .202 3.714
Nonmalignant diseases — 1 — —
VHD prophylaxis
In vivo T-cell depletion .556 .764 .311 1.875
Ex vivo  in vivo T-cell
depletion .986 — — —
CsA  MTX — 1 — —
VHD grade
III-IV .436 1.429 0.583 3.508
0-II — 1 — —
R indicates relative risk; CL, conﬁdence limits; MSD, matched
sibling donor; UD, unrelated donor; PMFD, partially matched
family donor; TBI, total body irradiation; CsA, cyclosporin A;rMTX, methotrexate; GVHD, graft-versus-host disease.
02owever, in some cases, the fatal outcome of urinary
ract obstruction, including bladder tamponade fol-
owed by renal failure, has been described [5,7]. In this
tudy, we investigated the incidence, etiology, risk
actors, and clinical management of HC in 102 chil-
ren and adolescents who underwent alloHCT in the
epartment of Pediatric Hematology, Oncology and
one Marrow Transplantation, Wroclaw Medical
niversity, from December 2001 to September 2004.
Seven patients who underwent transplantation in
ur institution were diagnosed with severe late-onset
C before the identiﬁcation of viruses in urine was
vailable. In 2 of these patients, rapid progression of
C, resulting in urinary tract obstruction followed by
enal failure, was considered the main cause of death
30]. This observation prompted us to initiate a reg-
lar screening of patients’ plasma and urine for HPV
nd AdV, the main causative agents of HC, with a
ualitative PCR-based assay. Viral DNA was detected
n the urine of 54.9% patients. BKV viruria was the
ost common (47%), and its frequency was signiﬁ-
antly higher in older patients. A surprisingly low
ncidence (12.5%) of BKV viruria was found among
hildren who received transplants from PMFDs de-
pite the profound immunosuppression caused by
ombined ex vivo and in vivo T-cell depletion. Our
bservation differs from those of an adult study in
hich the incidence of BKV viruria in patients after T
ell–depleted SCT was high [13]. However, to maxi-
ize the stem cell dose, we have performed transplan-
ations from PMFDs predominantly in young chil-
ren (10 years of age). These observations may
ndirectly conﬁrm the mechanism of BKV reactivation
ather than de novo infection, as was suggested by
thers [11,31]. Few studies have evaluated the preva-
ence of JCV infection in patients after SCT. In our
tudy group, JCV was found in the urine of only 4
3.9%) children, including 1 with JCV viremia, which
s similar to the observations of Arthur et al [11].
AdV viruria was not frequent in our patients. It
as detected in 4 children, in 3 of whom concomitant
dV viremia was also documented. In contrast to
dV, BKV viremia accompanied viruria in only 10 of
8 BKV-positive children.
The overall incidence of HC (25.3%) was higher
n comparison to that in other pediatric studies, which
eported frequencies of HC after SCT ranging from
% to 17% [6,14,31-34]. In all 26 patients with symp-
oms of HC in our study group, viruria was docu-
ented: BKV was identiﬁed in 21 (80%) patients,
dV in 4 (15.4%), and JCV in 1 (3.8%). This obser-
ation suggests that viruria is imperative for HC. The
linical pattern and incidence of HC may depend on
he virus type; therefore, we analyzed cases of AdV-
nd HPV-related HC separately. All 4 patients with
dV viruria developed HC, and this suggests a strong
elationship between viruria and clinical symptoms.
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Hemorrhagic Cystitis in Children and Adolescents after Allogeneic HCT
Bhe clinical course (not modiﬁed by antiviral treat-
ent) of HC in 2 AdV-positive children was very
evere and resulted in 1 death. The other untreated
atient progressed to disseminated AdV disease and
ied. Our observation conﬁrms the need for immedi-
te initiation of cidofovir treatment in patients with
dV-related HC. This has also been proposed by
thers [26].
Among 52 patients with documented HPV shed-
ing, 22 (42%) presented with symptoms of HC. Sim-
larly to other reports, not all patients with HPV
iruria developed HC. Therefore, we analyzed addi-
ional risk factors for HC occurrence in HPV-positive
hildren. The only risk factor for this group of pa-
ients was a conditioning regimen based on chemo-
herapy. The correlation between previous use of Bu
r Cy and HC has been pointed out by several studies
31,33,34]. One can speculate that the use of alkylating
gents in conditioning, causing initial damage to the
ladder epithelium, may facilitate a subsequent viral
ytopathic effect. It is possible that later, both reacti-
ation of HPV in the urothelium irritated by cytostat-
cs and a possible immune reaction (not necessarily
onnected to GVHD) against virus leads to profound
amage of the bladder mucosa and results in symp-
oms of HC. In our study group, 60% of children
onditioned with chemotherapy-based preparative
egimens received a combination of Bu and Cy, and
herefore the effect of each drug could not be directly
ssessed. However, it seems that the combination of
u and Cy did not increase the risk of HC more than
ther chemotherapy-based conditioning regimens.
he correlation between HC and GVHD has been
reviously demonstrated [3,6,33]. In our group of pa-
ients, severe acute GVHD was not associated with a
igher risk of HC, in accordance with the observa-
ions of Sencer et al. [4] and El-Zimaity et al. [2]. Age,
ex, type of donor, immunosuppressive prophylaxis of
VHD and graft rejection were not identiﬁed in our
nalysis as signiﬁcant risk factors of HC, in contrast to
ome other reports [6,13,32,34].
HC associated with HPV infection is considered
o be a self-limited complication. However, it pro-
ongs hospitalization, may cause severe morbidity, and
an occasionally be fatal [8]. Reduction of immuno-
uppressive treatment to promote elimination of the
irus from the urine may result in clinical improve-
ent, as has been described for renal transplant re-
ipients [36]. However, in patients after alloHCT,
uch a strategy is limited by the risk of GVHD. Still,
he relationship between a high viral load and symp-
oms of HPV-induced HC has been demonstrated
37]. Therefore, inhibition of viral replication by an-
iviral agents seems justiﬁed. The in vitro data suggest
hat cidofovir is active against HPV, but its efﬁcacy in
he treatment of HPV-induced HC remains uncertain
27]. Cidofovir treatment was applied in 20 children
B&MTiagnosed with BKV or JCV viruria and progressing
ematuria (HC stage greater than II). There was no
C-related death in the treated group. HC progres-
ion to stage IV followed by complete resolution of
C symptoms after prolonged cidofovir treatment
ccurred in 1 case. Our data suggest that cidofovir
ay be beneﬁcial for patients with HPV-related HC:
t may prevent progression and death.
ONCLUSIONS
HC is a frequent complication after alloHCT. It
eems to be strongly related to AdV or HPV viruria.
hereas AdV viruria leads to the development of HC
n probably all patients, HPV viruria may be asymp-
omatic even in a profoundly immunocompromised
ost. One additional risk factor for the development of
C in HPV-positive patients is a chemotherapy-
ased conditioning regimen. Treatment with cidofo-
ir is feasible, and further studies are warranted to
valuate its activity in HC mediated by BKV or JCV.
EFERENCES
1. Childs R, Sanchez C, Engler H, et al. High incidence of adeno-
and polyomavirus-induced hemorrhagic cystitis in bone mar-
row transplantation for hematological malignancy following T
cell depletion and cyclosporine. Bone Marrow Transplant. 1998;
22:889-893.
2. El-Zimaity M, Saliba R, Chan K, et al. Hemorrhagic cystitis
after allogeneic stem cell transplantation: donor type matters.
Blood. 2004;12:4674-4680.
3. Sreber A, Shu XO, Defor T, Sencer S, Ramsay N. Risk factors
for severe hemorrhagic cystitis following BMT. Bone Marrow
Transplant. 1999;23:35-50.
4. Sencer H, Haake R, Weisdorf D. Hemorrhagic cystitis after
bone marrow transplantation. Risk factors and complications.
Transplantation. 1993;56:875-879.
5. Nagler A, Or R, Naparstek E, Varadi G, Slavin S. Second
allogeneic stem cell transplantation using nonmyeloablative
conditioning for patients who relapsed or developed secondary
malignancies following autologous transplantation. Exp Hema-
tol. 2000;28:1096-1104.
6. Cesaro S, Brugiolo A, Faraci M, et al. Incidence and treatment
of hemorrhagic cystitis in children given hematopoietic stem
cell transplantation: a survey from the Italian association of
pediatric hematology oncology-bone marrow transplantation
group. Bone Marrow Transplant. 2003;32:925-931.
7. Iwamoto S, Azuma E, Hori H, et al. BKV-associated fatal renal
failure following late-onset hemorrhagic cystitis in unrelated
bone marrow transplantation. Pediatr Hematol Oncol. 2002;
19:255-261.
8. Tagliabue A, Vallinoto C, Corti P, et al. Ureteral obstruction
following allogeneic bone marrow transplantation in children.
Pediatr Hematol Oncol. 2003;20:257-260.
9. Cox PJ. Cyclophosphamide cystitis—identiﬁcation of acrolein
as a causative agent. Biochem Pharmacol. 1979;28:2045-2049.
0. Pode D, Pelberg S, Steiner D. Busulfan-induced hemorrhagic
cystitis. J Urol. 1983;130:347-348.
803
11
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
E. Gorczynska et al.
81. Arthur R, Shah K, Charache P, Saral R. BK and JC virus
infections in recipients of bone marrow transplantation. J Infect
Dis. 1988;3:563-569.
2. Azzi A, Fanci R, Bosi A, et al. Monitoring of polyomavirus BK
viruria in bone marrow transplantation patients by DNA hy-
bridization assay and by polymerase chain reaction: an approach
to assess the relationship between BK viruria and haemorrhagic
cystitis. Bone Marrow Transplant. 1994;14:235-240.
3. Chakrabarti S, Osman H, Collingham K, Milligan DW. Poly-
oma viruria following T-cell-depleted allogeneic transplants
using Campath-1H: incidence and outcome in relation to graft
manipulation, donor type and conditioning. Bone Marrow
Transplant. 2003;31:379-386.
4. Vögeli T, Peinemann F, Burdach S, Ackermann R. Urological
treatment and clinical course of BK polyomavirus-associated
hemorrhagic cystitis in children after bone marrow transplan-
tation. Eur Urol. 1999;36:252-257.
5. Akiyama H, Kurosu T, Sakashita C, et al. Adenovirus is a key
pathogen in hemorrhagic cystitis associated with bone marrow
transplantation. Clin Infect Dis. 2001;32:1325-1330.
6. Spach DH, Bauwens JE, Myerson D, Mustafa MM, Bowden
RA. Cytomegalovirus-induced hemorrhagic cystitis following
bone marrow transplantation. Clin Infect Dis. 1993;16:142-144.
7. Comar M, D’Agaro P, Andolina M, et al. Hemorrhagic cystitis
in children undergoing bone marrow transplantation: putative
role for simian virus 40. Transplantation. 2004;78:544-588.
8. Kim YJ, Kim DW, Lee DG, et al. Human herpesvirus-6 as a
possible cause of encephalitis and hemorrhagic cystitis after
allogeneic hematopoietic stem cell transplantation. Leukemia.
2002;16:958-959.
9. Mulkamel L, Lupu A, de Kernion J. Alum irrigation for severe
bladder hemorrhage. J Urol. 1986;135:784-785.
0. Kumar S, Rosen P, Grabstald H. Intravesical formalin for the
control of intractable bladder hemorrhage secondary to cystitis
or cancer. J Urol. 1975;114:540-543.
1. Trigg ME, O’Reilly J, Rumelhart S, Morgan D, Holida M, de
Alarcon P. Prostaglandin E1 bladder instillation to control
severe hemorrhagic cystitis. J Urol. 1990;143:92-94.
2. Miller J, Burﬁeld G, Moretti K. Oral conjugated estrogen
therapy for treatment of hemorrhagic cystitis. J Urol. 1994;151:
1348-1350.
3. Sebe P, Garderet L, Traxer O, Nouri M, Gluckman E, Gattegno
B. Subtotal cystectomy with ileocystoplasty for severe hemor-
rhagic cystitis after bone marrow transplantation. Urology. 2001;
57:168xiv-168xvi.
4. Vianelli N, Renga M, Azzi A, et al. Sequential vidarabine
infusion in the treatment of polyoma virus-associated acute
haemorrhagic cystitis late after allogeneic bone marrow trans-
plantation. Bone Marrow Transplant. 2000;25:319-320.
045. Miyamura K, Hamaguchi M, Taji H, et al. Successful ribavirin
therapy for severe adenovirus hemorrhagic cystitis after alloge-
neic marrow transplantation from close HLA donors rather
than distant donors. Bone Marrow Transplant. 2000;25:545-548.
6. Nagafuji K, Aoki K, Kato K, et al. Cidofovir for treating
adenoviral hemorrhagic cystitis in hematopoietic stem cell
transplant recipients. Bone Marrow Transplant. 2004;34:909-
914.
7. Vats A, Shapiro R, Randhawa PS, et al. Quantitative viral load
monitoring and cidofovir therapy for the management of BK
virus-associated nephropathy in children and adults. Transplan-
tation. 2003;75:105-112.
8. Droller MJ, Saral R, Santos G. Prevention of cyclophospha-
mide-induced hemorrhagic cystitis. Urology. 1982;20:256-258.
9. Klingebiel T, Schlegel PG. GVHD: overview on pathophysi-
ology, incidence, clinical and biological features. Bone Marrow
Transplant. 1998;21(suppl 2):S45-S49.
0. Gorczynska E, Rybka K, Turkiewicz D, et al. Successful cido-
fovir treatment of late-onset hemorrhagic cystitis in children
after allogeneic hematopoietic cell transplantation [abstract
P769]. Bone Marrow Transplant. 2003;31(suppl 1):S228.
1. Peinemann F, de Villiers EM, Dorries K, Adams O, Vogeli TA,
Burdach S. Clinical course and treatment of haemorrhagic
cystitis associated with BK type of human polyomavirus in nine
paediatric recipients of allogeneic bone marrow transplants.
Eur J Pediatr. 2000;159:182-188.
2. Hale G, Rochester R, Heslop H, et al. Hemorrhagic cystitis
after allogeneic bone marrow transplantation in children: clin-
ical characteristics and outcome. Biol Blood Marrow Transplant.
2003;9:698-705.
3. Russell S, Vowels M, Vale T. Haemorrhagic cystitis in paedi-
atric bone marrow transplant patients: an association with in-
fective agents, GvHD and prior cyclophosphamide. Bone Mar-
row Transplant. 1994;13:533-539.
4. Kondo M, Kojima S, Kato K, Matsuyama T. Late-onset hem-
orrhagic cystitis after hematopoietic stem cell transplantation in
children. Bone Marrow Transplant. 1998;22:995-998.
5. Cartoni C, Arcese W, Avvisati G, Corinto L, Capua A, Meloni
G. Role of ultrasonography in the diagnosis and follow-up of
hemorrhagic cystitis after bone marrow transplantation. Bone
Marrow Transplant. 1993;12:463-467.
6. Binet I, Nickeleit V, Hirsch HH, et al. Polyomavirus disease
under new immunosuppressive drugs. Transplantation. 1999;67:
918-922.
7. Leung AY, Suen CK, Lie AK, et al. Quantiﬁcation of polyoma
BK viruria in hemorrhagic cystitis complicating bone marrow
transplantation. Blood. 2001;6:1971-1978.
